Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Molecular diagnosis and MRD monitoring in AML

Jacqueline Cloos • 29 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia

Jacqueline Cloos, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, gives an update on the role of molecular diagnosis and measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jacqueline Cloos

1:20
The prognostic value of CD34+CD38- leukemic stem cell frequency in AML
Jacqueline Cloos • 20 Mar 2023
1:41
Implementing MRD in clinical practice for patients with intermediate-risk AML
Jacqueline Cloos • 20 Mar 2023
2:04
Novel techniques being used for MRD assessment in AML & the importance of considering oligoclonality
Jacqueline Cloos • 20 Mar 2023
0:52
The importance of evaluating heterogeneity in AML and how this may impact MRD assessment
Jacqueline Cloos • 20 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals